942 related articles for article (PubMed ID: 15688191)
1. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
3. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
4. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
7. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
8. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
[TBL] [Abstract][Full Text] [Related]
10. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?
Kotaniemi A; Piirainen H; Paimela L; Leirisalo-Repo M; Uoti-Reilama K; Lahdentausta P; Ruotsalainen P; Kataja M; Väisänen E; Kurki P
J Rheumatol; 1996 Nov; 23(11):1875-9. PubMed ID: 8923359
[TBL] [Abstract][Full Text] [Related]
11. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
12. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
13. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
Tekeoğlu I; Adak B; Budancamanak M; Demirel A; Ediz L
Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
[TBL] [Abstract][Full Text] [Related]
15. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
17. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Yilmaz L; Ozoran K; Gündüz OH; Uçan H; Yücel M
Rheumatol Int; 2001 Feb; 20(2):65-9. PubMed ID: 11269535
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
19. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
